Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT01381861Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Jul 2011
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carotuximab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by TRACON Pharmaceuticals, Inc. Primary endpoints: Progression-free Survival Rate at 6 months, Objective Tumor Response and 1 more. Started Jul 2011; status: completed.
02
Drugs
carotuximab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01381861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381861.